Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 7/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458309 | 0.95 | LPL (0.47) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL6736805 | 0.93 | LPL (0.49) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL8082305 | 0.92 | FAAH (0.46) | CA1CA2ENPP2KDR | |
| SCHEMBL29954452 | 0.92 | SMPD1 (0.48) | CA1CA2CYP1A2MAPTENPP2 | |
| SCHEMBL3791885 | 0.91 | MAPT (0.47) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL29954628 | 0.86 | ESR1 (0.51) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL257737 | 0.85 | ENPP2 (0.56) | CA1CA2LPLLIPGMAPT | |
| SCHEMBL29956963 | 0.85 | ENPP2 (0.43) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL3789212 | 0.85 | CYP1A2 (0.53) | CA1CA2LPLLIPGTRPV1 | |
| SCHEMBL29953148 | 0.85 | THRA (0.44) | CA1CA2LPLLIPGTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654404-B2 | Light emitting droplets and related methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-23 | — | — | US | disclosed |
| EP-2818531-B1 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-1534722-B1 | RHODIUM AND IRIDIUM COMPLEXES | MERCK PATENT GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9567526-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| EP-2842974-A1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20140375943-A1 | POLYMERIZABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| EP-2289902-A2 | Rhodium and iridium complexes | Merck Patent GmbH (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-7883785-B2 | 5'-mono-, 5',5''-bis- and 5',5'',5'''-tris-aryl/heteroaryl-functionalized tris-orthometallated organorhodium and organoiridium compounds; readily soluble triplet emitters | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-2256125-A2 | Rhodium and iridium complexes | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20060127696-A1 | Rhodium and iridium complexes | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CA1 3273/4885CA2 1992/4885LPL 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.